Amylin's metreleptin reduces blood glucose, improves diabetes

06/6/2011 | Drug Store News · Forbes

Amylin Pharmaceuticals' metreleptin drug, which functions like the hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy, experts reported at the annual meeting of The Endocrine Society in Boston. The firm said those who took metreleptin had reduced blood glucose and triglyceride levels and most were able to reduce or stop taking other diabetes medications.

View Full Article in:

Drug Store News · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI